983-P： CGM 测量的未使用胰岛素治疗的 2 型糖尿病成人血糖控制的长期改善--真实世界数据

IF 6.2 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes Pub Date : 2024-06-21 DOI:10.2337/db24-983-p

JENNIFER E. LAYNE, LAUREN H. JEPSON, ALEXANDER CARITE, RICHARD M. BERGENSTAL

{"title":"983-P： CGM 测量的未使用胰岛素治疗的 2 型糖尿病成人血糖控制的长期改善--真实世界数据","authors":"JENNIFER E. LAYNE, LAUREN H. JEPSON, ALEXANDER CARITE, RICHARD M. BERGENSTAL","doi":"10.2337/db24-983-p","DOIUrl":null,"url":null,"abstract":"Objectives: Emerging evidence indicates that CGM use is associated with improvements in glycemic control in adults with noninsulin treated T2D. This real-world study evaluated CGM metrics for one year after CGM initiation in this population. Methods: Data were analyzed from Dexcom G6 and G7 users who self-reported: T2D, ≥18 yr, gender, no insulin use and had baseline TIR ≤70%. Outcomes were change in CGM metrics from baseline to 6 months and 1 year, and proportion with TIR &gt;70% at follow-up overall and for younger (&lt;65 yr) and older (≥65 yr) cohorts. Results: CGM users (n=3,840) were: mean (SD): 52.5 (11.2) yr, 48% female, TIR 70-180 mg/dL 41.7% (21.4) and 12.4% of participants were ≥65 yr. Significant improvement was observed at 6 months with continued improvement at 1 year (Table) for all CGM metrics not at target values at baseline. The proportion of CGM users meeting TIR &gt;70% increased from 0% to 37.9% at 6 months and to 43.1% at 1 year. CGM was worn 84.7% of days. Outcomes were very similar for younger and older adults. One exception of note was the change in the TITR 70-140 mg/dL at 1 year, &lt;65 yr: +17.1% and ≥65 yr: +12.7%, but the &lt;65 yr group started with a lower baseline TITR. Conclusion: In this large, real-world study of adults with suboptimally controlled T2D not using insulin, CGM use was associated with meaningful improvements in glycemic control at 6 months with ongoing improvement at 1 year. Disclosure J.E. Layne: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. Employee; Verily Life Sciences. L.H. Jepson: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. A. Carite: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. R.M. Bergenstal: Other Relationship; Abbott. Research Support; Arkray Marketing. Consultant; Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur. Other Relationship; Dexcom, Inc., Eli Lilly and Company. Consultant; embecta, Hygieia. Research Support; Insulet Corporation. Consultant; MannKind Corporation. Other Relationship; Medtronic, Novo Nordisk. Consultant; Onduo LLC, Roche Diabetes Care. Other Relationship; Sanofi. Research Support; Tandem Diabetes Care, Inc. Other Relationship; UnitedHealth Group. Consultant; Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":null,"pages":null},"PeriodicalIF":6.2000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"983-P: Long-Term Improvement in CGM-Measured Glycemic Control in Adults with Type 2 Diabetes Not Treated with Insulin—Real-World Data\",\"authors\":\"JENNIFER E. LAYNE, LAUREN H. JEPSON, ALEXANDER CARITE, RICHARD M. BERGENSTAL\",\"doi\":\"10.2337/db24-983-p\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: Emerging evidence indicates that CGM use is associated with improvements in glycemic control in adults with noninsulin treated T2D. This real-world study evaluated CGM metrics for one year after CGM initiation in this population. Methods: Data were analyzed from Dexcom G6 and G7 users who self-reported: T2D, ≥18 yr, gender, no insulin use and had baseline TIR ≤70%. Outcomes were change in CGM metrics from baseline to 6 months and 1 year, and proportion with TIR &gt;70% at follow-up overall and for younger (&lt;65 yr) and older (≥65 yr) cohorts. Results: CGM users (n=3,840) were: mean (SD): 52.5 (11.2) yr, 48% female, TIR 70-180 mg/dL 41.7% (21.4) and 12.4% of participants were ≥65 yr. Significant improvement was observed at 6 months with continued improvement at 1 year (Table) for all CGM metrics not at target values at baseline. The proportion of CGM users meeting TIR &gt;70% increased from 0% to 37.9% at 6 months and to 43.1% at 1 year. CGM was worn 84.7% of days. Outcomes were very similar for younger and older adults. One exception of note was the change in the TITR 70-140 mg/dL at 1 year, &lt;65 yr: +17.1% and ≥65 yr: +12.7%, but the &lt;65 yr group started with a lower baseline TITR. Conclusion: In this large, real-world study of adults with suboptimally controlled T2D not using insulin, CGM use was associated with meaningful improvements in glycemic control at 6 months with ongoing improvement at 1 year. Disclosure J.E. Layne: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. Employee; Verily Life Sciences. L.H. Jepson: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. A. Carite: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. R.M. Bergenstal: Other Relationship; Abbott. Research Support; Arkray Marketing. Consultant; Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur. Other Relationship; Dexcom, Inc., Eli Lilly and Company. Consultant; embecta, Hygieia. Research Support; Insulet Corporation. Consultant; MannKind Corporation. Other Relationship; Medtronic, Novo Nordisk. Consultant; Onduo LLC, Roche Diabetes Care. Other Relationship; Sanofi. Research Support; Tandem Diabetes Care, Inc. Other Relationship; UnitedHealth Group. Consultant; Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S.\",\"PeriodicalId\":11376,\"journal\":{\"name\":\"Diabetes\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2024-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2337/db24-983-p\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db24-983-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的：新的证据表明，CGM 的使用与非胰岛素治疗的成人 T2D 患者血糖控制的改善有关。这项真实世界研究评估了该人群使用 CGM 一年后的 CGM 指标。方法：对 Dexcom G6 和 G7 用户的数据进行了分析，这些用户自我报告：T2D、≥18 岁、性别、未使用胰岛素且基线 TIR ≤70%。结果是 CGM 指标从基线到 6 个月和 1 年的变化，以及总体和年轻组（<65 岁）和年长组（≥65 岁）随访时 TIR >70% 的比例。结果CGM 用户（n=3,840）的平均年龄（SD）：52.5（11.2）岁，48% 为女性，TIR 70-180 mg/dL 41.7% (21.4)，12.4% 年龄≥65 岁。达到 TIR >70% 的 CGM 用户比例从 0% 增加到 6 个月时的 37.9%，1 年时增加到 43.1%。佩戴 CGM 的天数占 84.7%。年轻人和老年人的结果非常相似。值得注意的一个例外是 1 年时 TITR 70-140 mg/dL 的变化，<65 岁：+17.1%，≥65 岁：+12.7%：+12.7%，但<65 岁组开始时的基线 TITR 较低。结论在这项针对未使用胰岛素、血糖控制不理想的 T2D 成人的大型真实世界研究中，CGM 的使用与 6 个月血糖控制的显著改善相关，并且在 1 年后仍有持续改善。信息披露 J.E. Layne：员工；Dexcom，Inc.股票/股东；Dexcom, Inc.员工；Verily 生命科学公司。L.H. Jepson：员工；Dexcom, Inc.股票/股东; Dexcom, Inc.A. Carite：员工；Dexcom, Inc.股票/股东; Dexcom, Inc.R.M. Bergenstal：其他关系；雅培。研究支持; Arkray Marketing.顾问；Ascensia Diabetes Care、Bigfoot Biomedical, Inc.、CeQur.其他关系；Dexcom 公司、礼来公司。顾问；embecta、Hygieia。研究支持；Insulet 公司。顾问；MannKind 公司。其他关系；美敦力、诺和诺德。顾问；Onduo LLC、罗氏糖尿病护理公司。其他关系；赛诺菲。研究支持；Tandem Diabetes Care, Inc.其他关系；联合健康集团。顾问；Vertex Pharmaceuticals Incorporated、Zealand Pharma A/S。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

983-P: Long-Term Improvement in CGM-Measured Glycemic Control in Adults with Type 2 Diabetes Not Treated with Insulin—Real-World Data

Objectives: Emerging evidence indicates that CGM use is associated with improvements in glycemic control in adults with noninsulin treated T2D. This real-world study evaluated CGM metrics for one year after CGM initiation in this population. Methods: Data were analyzed from Dexcom G6 and G7 users who self-reported: T2D, ≥18 yr, gender, no insulin use and had baseline TIR ≤70%. Outcomes were change in CGM metrics from baseline to 6 months and 1 year, and proportion with TIR >70% at follow-up overall and for younger (<65 yr) and older (≥65 yr) cohorts. Results: CGM users (n=3,840) were: mean (SD): 52.5 (11.2) yr, 48% female, TIR 70-180 mg/dL 41.7% (21.4) and 12.4% of participants were ≥65 yr. Significant improvement was observed at 6 months with continued improvement at 1 year (Table) for all CGM metrics not at target values at baseline. The proportion of CGM users meeting TIR >70% increased from 0% to 37.9% at 6 months and to 43.1% at 1 year. CGM was worn 84.7% of days. Outcomes were very similar for younger and older adults. One exception of note was the change in the TITR 70-140 mg/dL at 1 year, <65 yr: +17.1% and ≥65 yr: +12.7%, but the <65 yr group started with a lower baseline TITR. Conclusion: In this large, real-world study of adults with suboptimally controlled T2D not using insulin, CGM use was associated with meaningful improvements in glycemic control at 6 months with ongoing improvement at 1 year. Disclosure J.E. Layne: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. Employee; Verily Life Sciences. L.H. Jepson: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. A. Carite: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. R.M. Bergenstal: Other Relationship; Abbott. Research Support; Arkray Marketing. Consultant; Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur. Other Relationship; Dexcom, Inc., Eli Lilly and Company. Consultant; embecta, Hygieia. Research Support; Insulet Corporation. Consultant; MannKind Corporation. Other Relationship; Medtronic, Novo Nordisk. Consultant; Onduo LLC, Roche Diabetes Care. Other Relationship; Sanofi. Research Support; Tandem Diabetes Care, Inc. Other Relationship; UnitedHealth Group. Consultant; Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.